Posted by Michael Wonder on 21 Nov 2019
Allogeneic hematopoietic cell transplantation and other expensive cellular therapies: a miracle for the few but off limits to many?
15 November 2019 - The number of patients undergoing allogeneic hematopoietic cell transplantation (HCT) for treatment of malignant and nonmalignant disorders has continued to grow worldwide.
Great progress has been made in overcoming HLA/immunologic barriers, but non-donor barriers to HCT persist. This represents a major unmet need because HCT is not accessible to everyone who would benefit from it.
In ethical terms, this is an unacceptable failure of distributive justice.
